Double-blind, Randomized, Non-inferiority Trial in Atopic Dermatitis: Comparison of Lipikar Balm and Relipid+ Balm in the Treatment of Mild to Moderate Atopic Dermatitis in Children and Adults
Starting soon · Not applicable
Conditions studied: Atopic Dermatitis, Emollients
In brief
The therapeutic cornerstone for mild to moderate forms of atopic dermatitis (AD) relies on the combination of topical corticosteroids and emollients. However, the daily application of emollients can be burdensome, leading to poor adherence, treatment fatigue, and therapeutic failure, often prompting a switch in emollient products. Emollients therefore represent a true therapeutic challenge. They also raise economic concerns, as they are not reimbursed by national health insurance, unlike topical corticosteroids. This results in an out-of-pocket expense for patients, adding a significant financial burden in the context of this chronic skin condition. Laboratoires Gilbert have developed and patented an active ingredient derived from seawater (Active Oligo Skin), formulated and produced at their pharmaceutical site in Hérouville Saint Clair. This active compound has shown promising in vitro and preclinical results in modulating inflammatory mechanisms involved in sensitive and atopic skin. The objective of this clinical trial is to compare the efficacy of Laboratoires Gilbert's patented emollient balm (Relipid+) with a reference emollient balm considered the "gold standard" and most frequently prescribed on the market (Lipikar Baume AP+M, La Roche-Posay) for atopic dermatitis. The hypothesis is that the test balm will be at least as effective as the gold standard (non-inferiority) in clinical terms, with an added benefit on microbiome diversity-an emerging and critical issue in the management of atopic dermatitis.
Key facts
- Study ID
- NCT07358000
- Run by
- University Hospital, Caen
- People needed
- 86
- Starts
- 2026-03-30
- Expected to finish
- 2026-12-01
- Last updated by the study team
- 2026-01-22
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Patients aged 6 months to 70 years with mild to moderate atopic dermatitis (SCORAD < 40)
- Time to treatment initiation < 72 hours between initial assessment and balm application
- Affiliated with the French national health insurance system and French-speaking
- Written informed consent must be obtained
You may not qualify if…
- Patients who decline participation
- Patients under legal guardianship, curatorship, legal protection, or judicial safeguard
- Patients with a SCORAD indicating the need for systemic therapy
Where it is running
- CHU Caen Normandie — Caen, Normandy, France
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.